| -1 week | 0 week | 2 week | 4 week | 1 month after Treatment Phase | 3 months after Treatment Phase |
---|---|---|---|---|---|---|
 | Baseline | Treatment phase | Follow-up Phase | |||
Patients | Â | Â | Â | Â | Â | Â |
Informed consent | X | Â | Â | Â | Â | Â |
Medical history | X | Â | Â | Â | Â | Â |
Physical examination | X | Â | Â | Â | Â | Â |
Randomization | Â | X | Â | Â | Â | Â |
Interventions | Â | Â | Â | Â | Â | Â |
Specific acupoints of Stomach meridians(n = 120) | Â | Â | Â | Â | Â | Â |
Non-specific acupoints of Stomach meridians(n = 120) | Â | 20 sessions of acupuncture at acupoints | Â | Â | ||
Acupoints of Shu and Mu acupoints(n = 120) | Â | Â | Â | Â | Â | Â |
Acupoints of Gallbladder meridians(n = 120) | Â | Â | Â | Â | Â | Â |
Comparisons | Â | Â | Â | Â | Â | Â |
Non-acupoints control group(n = 120) | Â | 20 sessions of acupuncture at non-acupoints | Â | Â | ||
Itopride control group(n = 120) | Â | 50 mg three times daily, 20 days treatment | Â | Â | ||
Outcomes a | Â | Â | Â | Â | Â | Â |
NDI | Â | X | X | X | X | X |
SID | Â | X | X | X | X | X |
SF-36 | Â | X | Â | X | X | X |
Participants safety | Â | Â | Â | Â | Â | Â |
Laboratory test | Â | X | Â | X | Â | Â |
Adverse events | Â | X | X | X | X | X |